MY ACCOUNT | NEWSLETTER |

China reports the first human case of H3N8 bird flu


China has recorded its first human infection with the H3N8 strain of bird flu. The country's health authorities have insisted that the risk of it spreading between people is low.

The variant of the virus was found on April 5 in a four-year-old boy from the central province of Henan who had a fever and other symptoms, the Chinese National Health Commission said in a statement collected by the Reuters agency. The boy had been in contact with chickens and crows raised in his home, he added.

Genome rearrangement

The H3N8 variant is common in horses and dogs and has even been found in seals. No human cases of H3N8 have been reported, health authorities said. Whole-genome sequence analyzes indicate that the H3N8 virus in this human case is a rearrangement with genes from viruses that have previously been detected in poultry and wild birds, said Nicola Lewis, an avian flu expert at the Royal Veterinary College. From great Britain.

The virus warrants increased vigilance, said Erik Karlsson, deputy director of the Pasteur Institute's virology unit in Cambodia. His involvement in the 1889 influenza pandemic, known as the Russian flu, was "great concern about the risk of the virus," he added.

Infections in people are sporadic

China's huge wild and farmed bird populations of many species provide an ideal environment for avian viruses to mix and mutate. Some sporadically infect people, usually poultry workers. Last year, China reported the first human case of H10N3.

The health commission said an initial study showed the variant did not yet have the ability to infect humans effectively and the risk of a large-scale epidemic was low.

Although rare, human infections can lead to adaptive mutations that potentially allow these viruses to spread more easily in mammals, Karlsson said. "We have to be concerned about all the indirect events," he added.

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Feline injection site sarcomas

Like0
Dislike0

C-reactive protein concentrations in canine acute pancreatitis

Like0
Dislike0

A retrospective clinical investigation of the safety and adverse effects of pantoprazole in hospitalized ruminants

Like0
Dislike0

Dr. Marjorie Bercier Publishes Study on Novel Diagnostic Approach for Prevalent Elephant Virus

Like0
Dislike0

FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2025 - All Rights Reserved
ISSN 2768-198X

Top